Linda Grais Biography and Net Worth

Director of Icon

Dr. Linda Grais has served as a Non-Executive Director of ICON plc since July 2021 having previously served as a member of the PRA Health Sciences board from October 2015 to July 2021. Dr. Grais served as a member of the board of directors of Ocera Therapeutics, Inc. from January 2008 through December 2017, as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as member of the board of directors of Arca Biopharma, Inc from 2007 to 2024. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Linda Grais currently serves on the board of directors of Corvus Pharmaceuticals and is a member of its audit committee. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.

What is Linda Grais' net worth?: The estimated net worth of Linda Grais is at least $1.04 million as of August 11th, 2026. Grais owns 6,162 shares of Icon stock worth more than $1,040,577 as of August 17th. This net worth approximation does not reflect any other assets that Grais may own. Learn More about Linda Grais' net worth.
How do I contact Linda Grais?: The corporate mailing address for Grais and other Icon executives is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. Icon can also be reached via phone at (531) 291-2000. Learn More on Linda Grais' contact information.
Has Linda Grais been buying or selling shares of Icon?: During the last ninety days, Linda Grais has sold $138,167.89 in shares of Icon stock. Most recently, Linda Grais sold 841 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a transaction totalling $138,167.89. Following the completion of the sale, the director now directly owns 6,162 shares of the company's stock, valued at $1,012,354.98. Learn More on Linda Grais' trading history.
Who are Icon's active insiders?: Icon's insider roster includes Barry Balfe (CEO), Brennan Brendan (CFO), Bernard Clerkin (CFO), John Climax (Director), Linda Grais (Director), Eugene Mccague (Director), Ronan Murphy (Director), Ciaran Murray (Director), and Anne Whitaker (Director). Learn More on Icon's active insiders.
Are insiders buying or selling shares of Icon?: In the last year, insiders at the medical research company sold shares 8 times. They sold a total of 9,531 shares worth more than $1,565,763.95. The most recent insider tranaction occured on August, 11th when Director Linda Grais sold 841 shares worth more than $138,167.89. Insiders at Icon own 44.0% of the company. Learn More about insider trades at Icon.
Information on this page was last updated on 8/11/2026.

Linda Grais Insider Trading History at Icon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/11/2026	Sell	841	$164.29	$138,167.89	6,162

Linda Grais Buying and Selling Activity at Icon

Icon Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Today's Range

Now: $168.87

$161.16

$169.37

50 Day Range

MA: $162.50

$140.73

$180.24

2 Week Range

Now: $168.87

$66.57

$203.91

Volume

273,568 shs

Average Volume

1,365,096 shs

Market Capitalization

$12.93 billion

P/E Ratio

39.64

Dividend Yield

N/A

Beta

1.21